Faruqi and Faruqui, LLP Logo
Share this page

Acadia Pharmaceuticals, Inc. (ACAD)



INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Acadia Pharmaceuticals, Inc. (ACAD) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Acadia Pharmaceuticals, Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD).

The investigation focuses on whether the Company and its executives violated federal securities laws by issuance of certain statements.

On March 11, 2015, Acadia disclosed that it will delay submission of its New Drug Application for its experimental Parkinson’s disease drug, nuplazid, from this quarter to sometime in the second half of the year.  As well, Acadia announced that its long-time Chief Executive Officer will be stepping down.

Following this news, Acadia shares declined by $9.94 per share, or more than 22%, to close on March 12, 2015 at $34.82 per share. 

Take Action

If you invested in Acadia stock or options through March 11, 2015 and would like to discuss your legal rights, please contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Acadia’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 03/13/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.